The Wall Street Journal's Health Blog reports that Pfizer named Martin Mackay as the new chief of their struggling R&D program. Jacob Goldstein adds that Mackay, who has been at Pfizer for over ten years, is an odd choice since Pfizer had been looking to bring in fresh blood. Pfizer also announced the launch of a dedicated biotech unit in San Franciso that will be run by Corey Goodman.
So Much for New Ideas
Oct 05, 2007